Histogen Inc. (HSTO)
| Market Cap | 1.50M |
| Revenue (ttm) | 19,000 |
| Net Income (ttm) | -12.41M |
| Shares Out | 4.27M |
| EPS (ttm) | -3.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,951 |
| Open | 0.400 |
| Previous Close | 0.350 |
| Day's Range | 0.350 - 0.400 |
| 52-Week Range | 0.050 - 1.050 |
| Beta | 1.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2023 |
About HSTO
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of vari... [Read more]
Financial Performance
In 2022, Histogen's revenue was $3.77 million, an increase of 310.12% compared to the previous year's $919,000. Losses were -$10.48 million, -27.24% less than in 2021.
Financial StatementsNews
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has file...
Histogen Announces Second Adjournment of Special Meeting of Stockholders
Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PT Potential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved
Histogen Announces Adjournment of Special Meeting of Stockholders
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14, 202...
Histogen Announces Board Approval of Complete Liquidation and Dissolution
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved...
Conatus Global Opens the Door for Lucrative Funding from Top Tier Venture Capitalists
London, United Kingdom--(Newsfile Corp. - August 7, 2023) - Charles Karsten's family-office consortium, Conatus Global, opens doors to deals by bringing startups and investors face to face. Two world-...
Histogen to Explore Strategic Alternatives
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule ...
Histogen Reports First Quarter 2023 Results and Provides Business Update
Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Histogen Announces Online Publication in the Journal of Investigative Dermatology
Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, ...
Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University
Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan
Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use
The Newly Issued Patent is Expected to Provide Protection into 2040
Histogen Reports Year-End 2022 Results and Provides Business Update
Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...
Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments fo...
Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
MCLEAN, Va.--(BUSINESS WIRE)--Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19.
Histogen Hires Alfred P. Spada Ph.D.
Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...
Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-...
Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update
Closed $5M Financing in July
Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen Announces 1-for-20 Reverse Stock Split
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...
Histogen to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selectiv...
Histogen Reports First Quarter 2022 Financial Results and Provides Business Update
Received $3.75 Million Payment from Allergan
CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.
SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAV...
Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, ...
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase select...